The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies

被引:45
|
作者
Muz, Barbara [1 ]
de la Puente, Pilar [1 ]
Azab, Feda [1 ]
Luderer, Micah [1 ]
Azab, Abdel Kareem [1 ]
机构
[1] Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, St Louis, MO 63108 USA
关键词
MULTIPLE-MYELOMA CELLS; BONE-MARROW MICROENVIRONMENT; HEMATOPOIETIC STEM-CELLS; ACTIVATED PRODRUG TH-302; NF-KAPPA-B; INDUCIBLE FACTOR-1-ALPHA; IN-VIVO; HODGKIN-LYMPHOMA; LEUKEMIC-CELLS; SOLID TUMORS;
D O I
10.1158/1541-7786.MCR-14-0028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor hypoxia is a well-described phenomenon during the progression of solid tumors affecting cell signaling pathways and cell metabolism; however, its role in hematologic malignancies has not been given the same attention in the literature. Therefore, this review focuses on the comparative differences between solid and hematologic malignancies with emphasis on the role of hypoxia during tumorigenesis and progression. In addition, contribution of the bone marrow and angiogenic environment are also discussed. Insight is provided into the role of hypoxia in metastatic spread, stemness, and drug resistance in hematologic conditions. Finally, emerging therapeutic strategies such as small-molecule prodrugs and hypoxia-inducible factor (HIF) targeting approaches are outlined to combat hypoxic cells and/or adaptive mechanisms in the treatment of hematologic malignancies. (C) 2014 AACR.
引用
收藏
页码:1347 / 1354
页数:8
相关论文
共 50 条
  • [31] The role of next-generation sequencing in hematologic malignancies
    Cho, Young-Uk
    BLOOD RESEARCH, 2024, 59 (01)
  • [32] Toll-Like Receptors and their Role in Hematologic Malignancies
    Wolska, Anna
    Lech-Maranda, Ewa
    Robak, Tadeusz
    CURRENT MOLECULAR MEDICINE, 2009, 9 (03) : 324 - 335
  • [33] The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
    Podar, K
    Anderson, KC
    BLOOD, 2005, 105 (04) : 1383 - 1395
  • [34] The role of protein kinase C-alpha in hematologic malignancies
    Lahn, M
    Sundell, K
    Köhler, G
    ACTA HAEMATOLOGICA, 2006, 115 (1-2) : 1 - 8
  • [35] Editorial: The Emerging Role for PP2A in Hematologic Malignancies
    Ruvolo, Peter P.
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [36] Introduction: Hematologic malignancies: Is there a role for topoisomerase-I inhibitors?
    Kantarjian, H
    SEMINARS IN HEMATOLOGY, 1999, 36 (04) : 1 - 2
  • [37] Diagnostic role of cytology in serous effusions of patients with hematologic malignancies
    Savvidou, Kyriaki
    Dimitrakopoulou, Aglaia
    Kafasi, Nikolitsa
    Konstantopoulos, Konstantinos
    Vassilakopoulos, Theodore
    Angelopoulou, Maria
    Siakantaris, Marina
    Korkolopoulou, Penelope
    Kanavaros, Panagiotis
    Mikou, Panagiota
    DIAGNOSTIC CYTOPATHOLOGY, 2019, 47 (05) : 404 - 411
  • [38] The Role of Radiotherapy in Hematologic Malignancies in Children, Adolescents, and Young Adults
    Milgrom, Sarah A.
    Lo, Andrea C.
    SEMINARS IN RADIATION ONCOLOGY, 2025, 35 (01) : 47 - 56
  • [39] Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes
    Casadevall, N
    SEMINARS IN ONCOLOGY, 1998, 25 (03) : 12 - 18
  • [40] Role of PPAR Receptor and Ligands in the Pathogenesis and Therapy of Hematologic Malignancies
    Wu, Jian
    Zhang, Min
    Faircloth, Allison
    HEMATO, 2022, 3 (03): : 422 - 433